Disc Medicine, Inc.
NASDAQDisc Medicine enters September with a fresh analyst upgrade pulling in one direction and options traders turning more defensive than they've been in weeks — an unusual split for a biotech that has barely moved on the week. The most newsworthy development this week is from the Street. Wedbush raised its price target on IRON to $100 from $88 on September 2, maintaining…
Snapshot as of 15 Sept 2026
Disc Medicine enters September with a fresh analyst upgrade pulling in one direction and options traders turning more defensive than they've been in weeks — an unusual split for a biotech that has barely moved on the…
Disc Medicine heads into the final week of August with a striking disconnect: the stock has climbed 11% over the past month while the CEO has been consistently selling into that strength. The insider angle is the most…
IRON enters the final week of June with a provocative divergence: the stock is up 6.6% on the day and nearly 10% over the past month, yet the CEO and COO have been selling aggressively — and short interest remains…
Disc Medicine reports tomorrow with short conviction at its highest point in recent weeks — and the options market quietly shifting in the same direction. The dominant positioning story remains short interest, which…
Disc Medicine heads into its June 18 earnings report with short sellers quietly adding exposure and the ORTEX short score at a fresh weekly high. Short interest is the dominant story here. Bears have rebuilt their…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IRON — free to start on ORTEX.
Sign up for free →Open IRON on ORTEX